[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597709":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo blood and tissue sample collection and have their medical records reviewed throughout the study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":22,"role":23},"Evelyn A. Reynolds, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[31],{"facility":22,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Rochester","Minnesota","55905","United States",{"type":38,"coordinates":39},"Point",[40,41],-92.4699,44.02163,{"lat":41,"lon":40},[44,45],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100597709",false,"NCT07062016","Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","MC230601 Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned complete surgical staging at Mayo Clinic. Complete surgical staging includes at least total hysterectomy, bilateral salpingo-oophorectomy and lymph node assessment. Sentinel node mapping meets the criteria for lymph node assessment. Peritoneal cytology is recommended. Additional staging procedures such as pelvic and para-aortic nodal evaluation, omental biopsy or omentectomy, may also be utilized for staging in patients based on the clinical situation and at the surgeon's discretion\n* At least one preoperative or postoperative feature of aggressive disease \\[International Federation of Gynecology and Obstetrics (FIGO) staging used throughout this protocol\\]\n\n  * Preoperatively:\n\n    * Biopsy with grade 3 endometrioid endometrial cancer (EC) or non-endometrioid EC\n    * Patients with FIGO grade 1-2 EC with evidence of extrauterine disease on imaging (CT, MRI, or PET)\n  * Postoperatively:\n\n    * Endometrial cancer (FIGO) with one or more established risk factors:\n\n      * Non-endometrioid histology\n\n        * Grade 3\n      * Lymphovascular space invasion (LVSI), ≥ 50% of myometrial invasion, presence of isolated tumor cells (ITC) in a sentinel lymph node OR\n      * Stage II to IV (FIGO) EC\n* Provide written informed consent\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to provide mandatory tissue specimens for correlative research\n* Willingness to return to registering site for clinical follow-up\n\nExclusion Criteria:\n\n* Patient receiving or who has received neoadjuvant chemotherapy\n* Pre-operative pregnancy","FEMALE","18 Years",{"count":57,"type":58},100,"ESTIMATED","OBSERVATIONAL","This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.",[62,63,64,65,66],"Endometrial Carcinoma","Endometrial High Grade Endometrioid Adenocarcinoma","Stage II Endometrial Cancer","Stage III Endometrial Cancer","Stage IV Endometrial Cancer","2026-04-09",{"date":69,"type":70},"2026-04-13","ACTUAL",{"date":72,"type":70},"2025-10-01",{"date":74,"type":58},"2028-10-31",{"name":5,"class":6},1]